Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025 BayStreet.ca - Wed Jan 15, 8:06AM CST

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As the new year begins, the American Association for Cancer Research (AACR) has highlighted expert predictions...

ONCY : 0.7910 (-5.66%)
TYRA : 16.19 (+0.25%)
ZNTL : 2.24 (-6.28%)
ONC.TO : 1.16 (-4.13%)
CMPX : 2.60 (+4.00%)
CCCC : 3.94 (+2.07%)
C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology GlobeNewswire - Tue Jan 14, 6:00AM CST

CCCC : 3.94 (+2.07%)
C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference GlobeNewswire - Wed Jan 8, 6:00AM CST

CCCC : 3.94 (+2.07%)
C4 Therapeutics Reports Promising Phase 1 Clinical Trial Results for Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at ASH Annual Meeting Quiver Quantitative, Inc. - Sun Dec 8, 2024

Cemsidomide shows promising response rates in multiple myeloma and non-Hodgkin's lymphoma, with manageable safety profiles.Quiver AI SummaryC4 Therapeutics, Inc. presented promising clinical data at the...

CCCC : 3.94 (+2.07%)
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader GlobeNewswire - Sun Dec 8, 2024

CCCC : 3.94 (+2.07%)
Options button on browser by Pashalgnatov via iStock
Unusual Options Activity: Strategies for Success with Three Single-Letter Stocks Barchart - Fri Nov 29, 2024

Hidden within Wednesday’s 1,211 unusually active options were 22 calls and puts whose stock symbols have a single letter. It might not seem like a great investment strategy, but single-letter stocks...

AA : 39.53 (+1.59%)
C : 79.99 (+1.89%)
BAC : 46.53 (-0.24%)
D : 55.28 (+0.40%)
DDD : 3.08 (-0.96%)
JPM : 259.16 (+1.92%)
ICF : 60.46 (-0.08%)
CCCC : 3.94 (+2.07%)
NEE : 70.76 (-0.85%)
O : 54.62 (+0.07%)
C4 Therapeutics Appoints Steve Hoerter to Board of Directors to Strengthen Oncology Expertise Quiver Quantitative, Inc. - Wed Nov 20, 2024

C4 Therapeutics appoints Steve Hoerter to its Board, enhancing oncology expertise to advance targeted protein degradation innovations.Quiver AI SummaryC4 Therapeutics, Inc. has announced the appointment...

CCCC : 3.94 (+2.07%)
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors GlobeNewswire - Wed Nov 20, 2024

CCCC : 3.94 (+2.07%)
C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial GlobeNewswire - Wed Nov 6, 2024

CCCC : 3.94 (+2.07%)
C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire - Tue Nov 5, 2024

CCCC : 3.94 (+2.07%)

Barchart Exclusives

3 Recession-Proof Dividend Stocks To Buy Today Barchart - Fri Jan 17, 6:00PM CST
Companies with long track records of increasing dividends can be a sound way to generate income in retirement. There's three top companies to look at today. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot